Orgenesis collaborates with MIDA Biotech to establish point-of-care centers at hospitals and other medical institutions across western Europe

Orgenesis Inc (NASDAQ:ORGS) announced Thursday that it is collaborating with MIDA Biotech BV to establish point-of-care centers at hospitals and other medical institutions across western Europe. Orgenesis said it and MIDA plan to deploy Orgenesis Mobile Processing Units and Labs (OMPULs) at leading hospitals for the onsite development of promising cell and gene therapies and immunotherapies from MIDA.  The OMPULs are multi-purpose, mobile, autonomous good manufacturing practice (GMP) facilities used to develop, optimize, and manufacture cell and gene therapies at the point of care.  READ: Orgenesis collaboration with Madrid hospital to develop solid tumor treatment Celyvir enters second phase Via the collaboration, Orgenesis said the teams will align various hospitals with projects focused on scaling the therapies through to commercialization with regulatory compliance and governmental approval standards as guiding principles. Under the agreement, Orgenesis and MIDA will establish point-of-care centers and deploy OMPULs within leading hospitals in Italy, Germany, Spain and Benelux, as well as other activities including joint research, development, and validation activities related to the development of cell and gene therapies. “These agreements mark a major milestone towards the commercial launch of our OMPULs across Europe, and we believe provide further validation of our platform, as each of the respective hospitals conducted extensive due diligence and verification around our technology and capabilities prior to signing the agreements,” said Orgenesis CEO Vered Caplan in a statement. “We see MIDA as an ideal partner based on their established relationships with the leading medical centers across western Europe and their promising science. Our teams are aligned in the desire to help lower costs and eliminate the logistical nightmares of building a centralized production facility or cleanrooms in the hospitals, which can stand in the way of getting a therapy to market effectively.” Orgenesis said the additional sites will significantly expand its POCare Network capacity, which already includes active development centers in the US, Belgium, Israel, and South Korea, as well as a growing number of joint venture agreements with regional partners and ongoing therapeutic development programs. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham